FDA yesterday approved daprodustat tablets (Jesduvroq, GlaxoSmithKline) as the first oral treatment for anemia caused by chronic kidney disease for adults who have been receiving dialysis for at least 4 months. The product is not approved for patients who are not on dialysis. Other FDA-approved treatments for this condition are administered intravenously or subcutaneously. Pharmacologically a hypoxia-inducible factor prolyl hydroxylase inhibitor, daprodustat carries a boxed warning in its labeling describing an increased risk of thrombotic vascular events, including death, heart attack, stroke, and blood clots in the lungs, legs, or dialysis access site.
As part of a new collaboration dedicated to improving diabetes management, ASHP and the American Diabetes Association are cohosting a Feb. 6 webinar covering the 2023 standards of diabetes care. The speakers will be Robert A. Gabbay, MD, PhD, of the American Diabetes Association and Pamela L. Stamm, PharmD, CDE, BCPS, BCACP, FASHP, of Auburn University (representing ASHP).
Understanding Fatal Overdoses to Inform Product Development and Public Health Interventions to Manage Overdose is the topic of a virtual public meeting on Mar. 8–9. Sponsored by the FDA and the Reagan-Udall Foundation for the FDA, the meeting will include stakeholders, including people who use drugs, their families, harm reduction programs, clinicians, academic researchers, and federal partners. It will explore the evolving context surrounding fatal overdoses as participants will discuss epidemiological trends, drug supply changes, public health interventions to manage overdose, and drug development opportunities.